48,860
edits
Difference between revisions of "Talk:Prostate cancer with neuroendocrine differentiation"
Jump to navigation
Jump to search
Talk:Prostate cancer with neuroendocrine differentiation (view source)
Revision as of 18:55, 15 December 2023
, 18:55, 15 December 2023fix typos
(fix typos) |
|||
| Line 6: | Line 6: | ||
The tumour's morphology is NOT in keeping with small cell carcinoma (the tumour cells have too much cytoplasm) and NOT in keeping with large cell neuroendocrine carcinoma (the tumour cells have nucleoli occasionally and eosinophilic cytoplasm). | The tumour's morphology is NOT in keeping with small cell carcinoma (the tumour cells have too much cytoplasm) and NOT in keeping with large cell neuroendocrine carcinoma (the tumour cells have nucleoli occasionally and eosinophilic cytoplasm). | ||
The distinction between (A) carcinoma and (B) carcinoma with a neuroendocrine component is dependent on: (1) morphology and (2) neuroendocrine (NE) staining. This case has NE staining; however, it does | The distinction between (A) carcinoma and (B) carcinoma with a neuroendocrine component is dependent on: (1) morphology and (2) neuroendocrine (NE) staining. This case has NE staining; however, it does NOT have a typical NE morphology. As such, the case does NOT have a definite neuroendocrine component. | ||
It should be noted that NE marker positivity is predictive of hormone refractive disease.[1] Androgen receptor testing in this context has been described as being an additional useful test;[2] however, testing is not available in house. | It should be noted that NE marker positivity is predictive of hormone refractive disease.[1] Androgen receptor testing in this context has been described as being an additional useful test;[2] however, testing is not available in house. | ||